ACHIEVED RECORD REVENUES OF $254 MILLION AND RECORD ADJUSTED EBITDA OF $62.9 MILLION (All amounts in U.S. dollars unless otherwise indicated) ...

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative ...

This is an unusual lagging period for the U.S. stock market. Over any trailing 100-day period since 2010, the S&P 500 has ...

Following the company’s first quarter results, Desjardins analyst Benoit Poirier has trimmed his price target on Transat A.T.

The shut down and liquidation of all 80 Hudson’s Bay stores and e-commerce operations could begin as soon as today, the ...

MEG Energy's strong Q4-2024 results highlight resilience, a 100% FCF return model, and robust market positioning. Read the ...

Canada's main stock index rallied for a second straight day on Monday as some investors took the view that the recent selloff ...

Nvidia's insider selling was aggressive in 2024, with nearly $2 billion in net liquidated value. Read why I will remain at ...

Toronto's main stock index rallied on Friday as technology and financial shares led broad-based gains and Mark Carney was ...

MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December ...

It’s just getting started. That’s the takeaway from analyst Michael W. Freeman, who initiated coverage of AIDX with a price ...

Want some of the top Canadian stocks for your portfolio? Despite market volatility, there’s plenty of great picks right now, ...